CNBX Pharmaceuticals, Inc. is a clinical stage company, which engages in the discovery, development, and commercialization of cannabinoid-based products and technologies for the treatment of cancer. The company is headquartered in Bethesda, Maryland and currently employs 2 full-time employees. The company went IPO on 2007-07-02. The firm's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The firm indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
Follow-Up Questions
CEO của CNBX Pharmaceuticals Inc là ai?
Mr. Eyal Barad là Chief Executive Officer của CNBX Pharmaceuticals Inc, tham gia công ty từ 2017.
Hiệu suất giá của cổ phiếu CNBX như thế nào?
Giá hiện tại của CNBX là $0.0003, đã decreased 0% trong ngày giao dịch cuối cùng.
Chủ đề kinh doanh chính hoặc ngành của CNBX Pharmaceuticals Inc là gì?
CNBX Pharmaceuticals Inc thuộc ngành Pharmaceuticals và lĩnh vực là Health Care
Vốn hóa thị trường của CNBX Pharmaceuticals Inc là bao nhiêu?
Vốn hóa thị trường hiện tại của CNBX Pharmaceuticals Inc là $27.7K